Table 3 Frequency of anti-SAE occurrence in different myositis groups.

From: Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts

 

Western cohorts

Asian cohorts

Study

Betteridge

Tarricone

Betteridge

Bodoki

Fujimoto

Muro

Our study

 

[3]

[5]

[4]

[8]

[6]

[7, 9]

 

IIM

44

130

266

337

518

150

570

Adult DM

2/20 (10%)

5/75 (7%)

11/131 (8%)

4/73 (5%)

6/445 (1%)

7/138 (5%)

12/394 (3%)

PM

0/24

0/43

0/124

0/211

0/62

0

0/144

JDM

0

0/12

NA

0/17

1/11

0/12

0/32

F/M

1/1

NA

7/4

2/2

4/3

3/4

9/3

Heliotrope sign

2/2 (100%)

2/5 (40%)

9/11 (82%)

3/4 (75%)

4/7 (57%)

3/7 (43%)

9/12 (75%)

V sign

2/2 (100%)

NA

3/7 (43%)

1/4 (25%)

4/7 (57%)

5/7 (71%)

6/12 (50%)

Shawl sign

2/2 (100)

NA

3/7 (43%)

1/4 (25%)

6/7 (86%)

4/7 (57%)

6/12 (50%)

Gottron’s sign

2/2 (100%)

5/5 (100%)

9/11 (82%)

3/4 (75%)

6/7 (86%)

7/7 (100%)

9/12 (75%)

Muscular weakness

0/2 (0)

5/5 (100%)

11/11 (100%)

4/4 (100%)

6/7 (86%)

5/7 (71%)

8/12 (67%)

Periungal changes

2/2 (100%)

1/5 (20%)

8/8 (100%)

1/4 (25%)

5/5 (100%)

5/6 (83%)

NA

Arthralgia

NA

0/4 (0)

2/11 (18%)

2/4 (50%)

1/7 (14%)

0/7 (0)

4/11936%)

Elevated CK

2/2 (100%)

4/5 (80%)

9/11 (82%)

NA

5/7 (71%)

7/7 (100%)

6/11 (55%)

Dysphagia

2/2 (100%)

0/5 (0)

7/9 (78%)

3/4 (75%)

2/7 (29%)

3/7 (43%)

7/11 (64%)

ILD

2/2 (100%)

0/5 (0)

2/11 (18%)

1/4 (25%)

5/7 (71%)

5/7 (71%)

7/11 (64%)

Cancer

0/2 (0)

1/5 (20%)

2/11 (18%)

1/4 (25%)

1/7 (14%)

4/7 (57%)

2/11 (18%)

Back to article page